Logo
x

Search

Subscribe Now

Biocon

Biocon’s Yesafili (Biosimilar, Eylea) Receives the US FDA’s Approval for Ophthalmology

Biocon’s Yesafili (Biosimilar, Eylea) Receives the US FDA’s Approval for Ophthalmology

  • May 21, 2024
Biocon Enters into an Exclusive License Agreement with Bayer and Regeneron for the Commercialization of Yesafili (biosimilar, aflibercept) into the Canadian Market

Biocon Enters into an Exclusive License Agreement with Bayer and Regeneron for the Commercialization of Yesafili (biosimilar, afli...

  • March 4, 2024
Biocon Biologics Enters into a Exclusive License Agreement with Sandoz for the Commercialization of Ogivri (biosimilar, trastuzumab) and Abevmy (biosimilar, bevacizumab) to Treat Cancer

Biocon Biologics Enters into a Exclusive License Agreement with Sandoz for the Commercialization of Ogivri (biosimilar, trastuzuma...

  • February 9, 2024
PharmaShots Weekly Snapshots (October 09–13, 2023) _

PharmaShots Weekly Snapshots (October 09–13, 2023) _

  • October 14, 2023
Biocon Entered into a Commercialization Agreement with Juno Pharmaceuticals for Liraglutide to Treat Type 2 diabetes and Obesity in Canada

Biocon Entered into a Commercialization Agreement with Juno Pharmaceuticals for Liraglutide to Treat Type 2 diabetes and Obesity i...

  • October 10, 2023
Biocon Reports P-I Study (RHINE-3) Results of Biosimilar Insulin

Biocon Reports P-I Study (RHINE-3) Results of Biosimilar Insulin

  • December 25, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.